Publications

​Original articles regarding the BIOPAC study

Torphy RJ, Wang Z, True-Yasaki A, Volmar KE, Rashid N, Yeh B, Johansen JS, Hollingsworth MA, Yeh JJ, Collinson EA. Stromal content is correlated with tissue site, contrast retention, and survival in pancreatic adenocarcinoma. JCO Precis Oncol 2019, in press.

Obazee O and CanziaF, and the PANDORA consortium. Germline BRCA2K3326X and CHECK2I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Int J Cancer 2019, in press.

Mellby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard BG, Bojesen SE, Mitchell BL, Sheppard BC, Sears RC, Borrebaeck CAK. Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer. J Clin Oncol 2018;36:2887-2894 (IF 24.008).

Strell C, Norberg KJ, Mezheyeuski A, Schnittert J, Kuninty PR, Moro CF, Paulsson J, Schultz NA, Calatayud D, Löhr JM, Frings O, Verbeke CS, Heuchel RL, Prakash J, Johansen JS, Östman A. Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC. Br J Cancer 2017;117:65-77 (IF 6.176)

Chen I, Raymond VM, Geis JA, Collison EA, Jensen BV, Hermann HK, Erlander MG, Tempero M, Johansen JS. Ultrasensitive plasma ctDNAKRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic cancer. Oncotarget 2017;8:97769-97786 (IF 5.16).

Calatayud D, Dehlendorff C, Boisen MK, Hasselby JP, Schultz NA, Werner J, Immervoll H, Molven A, Hansen CP, Johansen JS. Tissue microRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers. Biomark Res 2017;5:8.

Laklai H, Miroshnikova YA, Pickup MW, Collison EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, LeBleu VS, Roy N, Novitskiy SV, Johansen JS,Poli V, Kalluri R, Lacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, Moses HL, Weaver VM. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med 2016;22:497-505 (IF 28.439).

Johansen JS, Calatayud D, Albieri V, Schultz NA, Dehlendorff C, Werner J, Jensen BV, Pfeiffer P, Bojesen SE, Giese N, Nielsen KR, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK. The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer.Int J Cancer 2016;139:2312-2324 (IF 5.531).

Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, Anagnostou V, Parpart-Li S, Murphy D, Kay Li Q, Hruban CA, Scharpf R, White JR, O'Dwyer PJ, Allen PJ, Eshleman JR, Thompson CB, Klimstra DS, Linehan DC, Maitra A, Hruban RH, Diaz LA Jr, Von Hoff DD, Johansen JS, Drebin JA, Velculescu VE. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun 2015;6:7686 (IF 11.470).

Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK, Johansen JS. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 2014;311:392-404 (IF 29.978).

Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, Bjerregård JK, Pfeiffer P, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, Wøjdemann M, Bojesen SE, Nielsen K, Johansen JS. Diagnostic and prognostic impact of circulating YKL-40 and IL-6 in patients with pancreatic cancer.PLOS One 2013;8:e67059 (IF 4.351).

Schultz NA, Werner J, Willenbrock H, Roslind A, Giese N, Horn T, Wøjdemann M, Johansen JS. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Modern Pathology 2012;25:1609-22 (IF 4.176).

Schultz NA, Roslind A, Christensen IJ, Horn T, Pedersen LN, Kruhøffer M, Burcharth F, Wøjdemann M, Johansen JS. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. Pancreas 2012;41:759-66 (IF 2.386).

Schultz NA, Andersen KK, Roslind A, Willenbrock H, Wøjdemann M, Johansen JS. Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer – five microRNAs in a prognostic index. World J Surgery 2012;36:2699-707 (IF 2.362).


Redaktør